Hematology NewsHigh-dose MTX-based chemo is well tolerated in older PCNSL patientsApril 24, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersRare Diseases
Hematology NewsMonitoring, early intervention key to CAR T safetyApril 24, 2019Cellular TherapyAggressive LymphomasImmunotherapyB Cell LymphomaTransplantationImmuno-oncologyLymphoma & Plasma Cell Disorders
Hematology NewsQuality of life decrement with salvage ASCT is short-livedApril 23, 2019Multiple MyelomaTransplantTransplantationLymphoma & Plasma Cell DisordersPatient & Survivor Care
Hematology NewsRIT consolidation may be an option for unfit MCL patientsApril 17, 2019Mantle Cell LymphomaB Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology TimesCreating CAR T-cell therapies for T-cell malignanciesApril 16, 2019ALLT Cell LymphomasLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationImmunotherapyCellular TherapyImmuno-oncology
Oncology PracticeDr. Louis Weiner: AACR presentations highlight new “transformative strategies”April 11, 2019Immuno-oncologyLymphoma & Plasma Cell Disorders
Hematology TimesIn situ vaccination produced responses in indolent NHLApril 8, 2019B Cell LymphomaIndolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsDA-EPOCH-R appears more toxic than standard R-CHOP in DLBCLApril 5, 2019B Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsPolatuzumab outperforms pinatuzumab in non-Hodgkin lymphomaApril 5, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsEarly data support R-BAC for post-BTKi mantle cell lymphomaApril 5, 2019Mantle Cell LymphomaB Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsASCO, CCO issue multiple myeloma treatment guidelinesApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology NewsReal world responses mirror TOURMALINE-MM1 dataApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology NewsPowerful breast-implant testimony constrained by limited evidenceApril 4, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsUNITY-NHL: Interim findings show activity, tolerability of umbralisib for R/R MZLApril 2, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsCombo could replace standard conditioning regimen for myelomaApril 2, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
